Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus nedaplatin and capecitabine versus nedaplatin and capecitabine for resectable esophageal or esophagogastric junction cancer
ChiCTR2100046285Phase 4Recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib in esophageal cancer and esophagogastric junction cancer (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoints: disease-free survival and overall survival. Started May 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2100046285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046285.